Questions across 24 calls

Sajal Kapoor

Antifragile Thinking

Neuland Laboratories Limited

Neuland Laboratories Limited CC-Dec24.pdf · 2025-02-11

Thanks for taking my question. Good afternoon, all. Only two questions I have. First is, any thoughts that you could share around this sudden kind of almost U -turn type of thinking from big pharma, big global innovators, they are now returning back to small molecule spaces. And there is a pattern developing. And this is not in the last one month or two. I mean, if you look what they have done over the last, let's say 18 months in particular, if not after COVID, there is a definite desire and i ntensity to come back to small molecules. I mean, is it related to patient compliance? The oral molecules are easier to administer or is it something to do with the cost or a combination? I mean, what is , because the reason I am asking is previously Big Pharma's statements was that biologics will rule the world and small molecules will be done and dusted with the R&D?

No, that's absolutely fine. Thank you for that, Saharsh. A question for you, Abhijit. so, you mentioned the free cash. I am asking about operating cash. What was the nine month operating cash after adjusting for all the working capital? So, the nine-month EBITDA is about Rs. 272 crores. How much of that has been converted to net operating cash adjusted for working capital?

Piramal Pharma Limited

Piramal Pharma Limited CC-Dec24.pdf · 2025-01-29

Many thanks for taking the questions. The intermediate and API supply chain, we know that is spread across the globe and it's pretty complex. So , given the recent posturing from the U.S. administration, I mean, how is the economics and the timeline of setting up a greenfield facility in the U.S. versus India?

And Peter, the pricing is different, right? If you want the product to be made in the U .S., the pricing will not be the same as in India, right?

Laurus Labs Limited

Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2025-01-24

First question is related to Laurus Bio. Recently, a 59-year-old female patient from Netherlands travelled to India for CAR-T cell therapy and her treatment was successful. And of course, this is a wonderful outcome for Indian scientists, doctors and health care infrastructure in the country, in particular. And I'm, of course, so proud to be an investor in ImmunoACT through Laurus Labs, of course. My question is about both ImmunoACT and our gene therapy Phase I progress at IIT Kanpur. Can these individually become multitherapy assets at scale?

That's helpful, Dr. Satya. And my second and last question is, given ou r reactors are interchangeable or fungible, we can always stop ARV and switch to NCE or higher -margin products in the same block where we are currently doing ARV today should an opportunity arise in the future. So I mean, logically thinking, instead of doi ng a 35% gross margin in a fungible reactor, we would rather do a 70% gross margin molecule. I mean, is that how you would think as well?

Laurus Labs Limited CC-Dec24.pdf · 2025-01-24

First question is related to Laurus Bio. Recently, a 59-year-old female patient from Netherlands travelled to India for CAR-T cell therapy and her treatment was successful. And of course, this is a wonderful outcome for Indian scientists, doctors and health care infrastructure in the country, in particular. And I'm, of course, so proud to be an investor in ImmunoACT through Laurus Labs, of course. My question is about both ImmunoACT and our gene therapy Phase I progress at IIT Kanpur. Can these individually become multitherapy assets at scale?

That's helpful, Dr. Satya. And my second and last question is, given ou r reactors are interchangeable or fungible, we can always stop ARV and switch to NCE or higher -margin products in the same block where we are currently doing ARV today should an opportunity arise in the future. So I mean, logically thinking, instead of doi ng a 35% gross margin in a fungible reactor, we would rather do a 70% gross margin molecule. I mean, is that how you would think as well?